Sex: F
Vaccine: COVID19, TDAP, VARZOS
Symptoms: Hypokinesia, Lymphoma, Neurological symptom
Clinical narrative: Stroke; Lymphoma; Lymphoma; Severe demyelination of brain; Neurological disease; Minimal movement in left arm ad left leg; Can't get out of bed or walk without help; Can't get out of bed or walk without help; This case was reported by a other health professional and described the occurrence of stroke in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis and COVID 19 MRNA VACCINE MODERNA for prophylaxis.   Previously administered products included Moderna vaccine (received 1st dose on 15th February 2021).   On 5th May 2021, the patient received the 1st dose of Shingrix and Tdap Vaccine. On 15th March 2021, the patient received the 2nd dose of COVID 19 MRNA VACCINE MODERNA. In May 2021, less than 3 weeks after receiving Shingrix and Tdap Vaccine, the patient experienced stroke (serious criteria GSK medically significant), acute disseminated encephalomyelitis (serious criteria GSK medically significant), lymphoma (serious criteria GSK medically significant), demyelination (serious criteria GSK medically significant), neurological symptom, movements reduced, bedridden and walking difficulty. On an unknown date, the outcome of the stroke, acute disseminated encephalomyelitis, lymphoma, demyelination, neurological symptom, movements reduced, bedridden and walking difficulty were not recovered/not resolved.   It was unknown if the reporter considered the stroke, acute disseminated encephalomyelitis, lymphoma, demyelination, neurological symptom, movements reduced, bedridden and walking difficulty to be related to Shingrix and Tdap Vaccine.  Additional details were provided as follows: The reporter was an epidemiology lead. The age at vaccination was not reported. The reporter knew someone whose mother (patient) received the Moderna and Shingrix vaccines and in May 2021, less than 3 weeks after receiving Shingrix and Tdap Vaccine and between 1 and 3 months after receiving Moderna vaccine, the patient developed some neurological symptoms. The symptoms were observed in mid-May 2021 and worsened by the day.  The patient went to emergency room on 7th June and again on 14th June 2021.  Initial diagnosis on 14th June 2021 was stroke but at the time of reporting it was undiagnosed neurological disease with severe demyelination of the brain.  The patient experienced minimal movement in left arm and left leg and could not get out of bed or walk without help. This was reported to VAERS.  The patient's son was also told that, it was most likely acute disseminated encephalomyelitis but now another doctor suggested lymphoma. The patient's son said he had been chasing ghosts with the doctors he had been sending the patient to and could not get a clear diagnosis. The reporter was reaching out to GlaxoSmithKline but was not sure if needed to report this to global safety. It was unknown if the reporter considered the stroke, acute disseminated encephalomyelitis, lymphoma, demyelination, neurological symptom, movements reduced, bedridden and walking difficulty to be related to Moderna vaccine.